Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Pulmonary Medicine
Published in: BMC Pulmonary Medicine 1/2014

Open Access 01-12-2014 | Research article

Pharmacologic inhibition of S-nitrosoglutathione reductase protects against experimental asthma in BALB/c mice through attenuation of both bronchoconstriction and inflammation

Authors: Joan P Blonder, Sarah C Mutka, Xicheng Sun, Jian Qiu, Lucia H Green, Navdeep K Mehra, Ramakrishna Boyanapalli, Michael Suniga, Kirsten Look, Chris Delany, Jane P Richards, Doug Looker, Charles Scoggin, Gary J Rosenthal

Published in: BMC Pulmonary Medicine | Issue 1/2014

Login to get access

Abstract

Background

S-nitrosoglutathione (GSNO) serves as a reservoir for nitric oxide (NO) and thus is a key homeostatic regulator of airway smooth muscle tone and inflammation. Decreased levels of GSNO in the lungs of asthmatics have been attributed to increased GSNO catabolism via GSNO reductase (GSNOR) leading to loss of GSNO- and NO- mediated bronchodilatory and anti-inflammatory actions. GSNOR inhibition with the novel small molecule, N6022, was explored as a therapeutic approach in an experimental model of asthma.

Methods

Female BALB/c mice were sensitized and subsequently challenged with ovalbumin (OVA). Efficacy was determined by measuring both airway hyper-responsiveness (AHR) upon methacholine (MCh) challenge using whole body plethysmography and pulmonary eosinophilia by quantifying the numbers of these cells in the bronchoalveolar lavage fluid (BALF). Several other potential biomarkers of GSNOR inhibition were measured including levels of nitrite, cyclic guanosine monophosphate (cGMP), and inflammatory cytokines, as well as DNA binding activity of nuclear factor kappa B (NFκB). The dose response, onset of action, and duration of action of a single intravenous dose of N6022 given from 30 min to 48 h prior to MCh challenge were determined and compared to effects in mice not sensitized to OVA. The direct effect of N6022 on airway smooth muscle tone also was assessed in isolated rat tracheal rings.

Results

N6022 attenuated AHR (ED50 of 0.015 ± 0.002 mg/kg; Mean ± SEM) and eosinophilia. Effects were observed from 30 min to 48 h after treatment and were comparable to those achieved with three inhaled doses of ipratropium plus albuterol used as the positive control. N6022 increased BALF nitrite and plasma cGMP, while restoring BALF and plasma inflammatory markers toward baseline values. N6022 treatment also attenuated the OVA-induced increase in NFκB activation. In rat tracheal rings, N6022 decreased contractile responses to MCh.

Conclusions

The significant bronchodilatory and anti-inflammatory actions of N6022 in the airways are consistent with restoration of GSNO levels through GSNOR inhibition. GSNOR inhibition may offer a therapeutic approach for the treatment of asthma and other inflammatory lung diseases. N6022 is currently being evaluated in clinical trials for the treatment of inflammatory lung disease.
Appendix
Available only for authorised users
Literature
1.
Hess DT, Matsumoto A, Kim SO, Marshall HE, Stamler JS: Protein S-nitrosylation: purview and parameters. Nat Rev Mol Cell Biol. 2005, 6: 150-166. 10.1038/nrm1569.CrossRefPubMed
2.
Hogg N: The biochemistry and physiology of S-nitrosothiols. Annu Rev Pharmacol Toxicol. 2002, 42: 585-600. 10.1146/annurev.pharmtox.42.092501.104328.CrossRefPubMed
3.
Gaston B, Reilly J, Drazen JM, Fackler J, Ramdev P, Arnelle D, Mullins ME, Sugarbaker DJ, Chee C, Singel DJ: Endogenous nitrogen oxides and bronchodilator S-nitrosothiols in human airways. Proc Natl Acad Sci USA. 1993, 90: 10957-10961. 10.1073/pnas.90.23.10957.CrossRefPubMedPubMedCentral
4.
Kelm M, Schrader J: Control of coronary vascular tone by nitric oxide. Circ Res. 1990, 66: 1561-1575. 10.1161/01.RES.66.6.1561.CrossRefPubMed
5.
Foster MW, Hess DT, Stamler JS: Protein S-nitrosylation in health and disease: a current perspective. Trends Mol Med. 2009, 15: 391-404. 10.1016/j.molmed.2009.06.007.CrossRefPubMedPubMedCentral
6.
7.
Fortenberry JD, Owens ML, Chen NX, Brown LA: S-nitrosoglutathione inhibits TNF-alpha-induced NFkappaB activation in neutrophils. Inflamm Res. 2001, 50: 89-95. 10.1007/s000110050729.CrossRefPubMed
8.
Ricciardolo FL, Sterk PJ, Gaston B, Folkerts G: Nitric oxide in health and disease of the respiratory system. Physiol Rev. 2004, 84: 731-765. 10.1152/physrev.00034.2003.CrossRefPubMed
9.
Whalen EJ, Foster MW, Matsumoto A, Ozawa K, Violin JD, Que LG, Nelson CD, Benhar M, Keys JR, Rockman HA, Koch WJ, Daaka Y, Lefkowitz RJ, Stamler JS: Regulation of β-adrenergic receptor signaling by s-nitrosylation of g protein-coupled receptor kinase 2. Cell. 2007, 129: 511-522. 10.1016/j.cell.2007.02.046.CrossRefPubMed
10.
11.
Liu L, Hausladen A, Zeng M, Que L, Heitman J, Stamler JS: A metabolic enzyme for S-nitrosothiol conserved from bacteria to humans. Nature. 2001, 410: 490-494. 10.1038/35068596.CrossRefPubMed
12.
Gaston B, Singel D, Doctor A, Stamler JS: S-nitrosothiol signaling in respiratory biology. Am J Respir Crit Care Med. 2006, 173: 1186-1193. 10.1164/rccm.200510-1584PP.CrossRefPubMedPubMedCentral
13.
Que LG, Yang Z, Stamler JS, Lugogo NL, Kraft M: S-nitrosoglutathione reductase – an important regulator in human asthma. Am J Respir Crit Care Med. 2009, 180: 226-231. 10.1164/rccm.200901-0158OC.CrossRefPubMedPubMedCentral
14.
Gaston B, Sears S, Woods J, Hunt J, Ponaman M, McMahon T, Stamler JS: Bronchodilator S-nitrosothiol deficiency in asthmatic respiratory failure. Lancet. 1998, 351: 1317-1319. 10.1016/S0140-6736(97)07485-0.CrossRefPubMed
15.
Choudhry S, Que LG, Yang Z, Liu L, Eng C, Kim SO, Kumar G, Thyne S, Chapela R, Rodriguez-Santana JR, Rodriguez-Cintron W, Avila PC, Stamler JS, Burchard EG: GSNO reductase and beta2-adrenergic receptor gene-gene interaction: bronchodilator responsiveness to albuterol. Pharmacogenet Genomics. 2010, 6: 351-358.CrossRef
16.
Moore PE, Ryckman KK, Williams SM, Patel N, Summar ML, Sheller JR: Genetic variants of GSNOR and ADRB2 influence response to albuterol in African-American children with severe asthma. Pediatr Pulmonol. 2009, 44: 649-654. 10.1002/ppul.21033.CrossRefPubMed
17.
Wu H, Romieu I, Sienra-Monge JJ, Estela DR-N, Anderson DM, Jenchura CA, Li H, Ramirez-Aguilar M, Del CL-SI, London SJ: Genetic variation in S-nitrosoglutathione reductase (GSNOR) and childhood asthma. J Allergy Clin Immunol. 2007, 120: 322-328. 10.1016/j.jaci.2007.04.022.CrossRefPubMedPubMedCentral
18.
Que LG, Liu L, Yan Y, Whitehead GS, Gavett SH, Schwartz DA, Stamler JS: Protection from experimental asthma by an endogenous bronchodilator. Science. 2005, 308: 1618-1621. 10.1126/science.1108228.CrossRefPubMedPubMedCentral
19.
Gelb AF, Taylor CF, Nussbaum E, Gutierrez C, Schein A, Shinar CM, Schein MJ, Epstein JD, Zamel N: Alveolar and airway sites of nitric oxide inflammation in treated asthma. Am J Respir Crit Care Med. 2004, 170: 737-741. 10.1164/rccm.200403-408OC.CrossRefPubMed
20.
Redington AE: Modulation of nitric oxide pathways: therapeutic potential in asthma and chronic obstructive pulmonary disease. Eur J Pharmacol. 2006, 533: 263-276. 10.1016/j.ejphar.2005.12.069.CrossRefPubMed
21.
Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR: Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med. 2005, 352: 2163-2173. 10.1056/NEJMoa043596.CrossRefPubMed
22.
Maddaford S, Annedi SC, Ramnauth J, Rakhit S: Advances in the development of nitric oxide synthase inhibitors. Annual Reports in Medicinal Chemistry. Volume 44. Edited by: Macor JE. 2009, Salt Lake City: Elsevier, Inc, 27-50.CrossRef
23.
Vallance P, Leiper J: Blocking NO synthesis: how, where and why?. Nat Rev Drug Discov. 2002, 1: 939-950. 10.1038/nrd960.CrossRefPubMed
24.
Al-Sa’doni H, Ferro A: S-Nitrosothiols: a class of nitric oxide-donor drugs. Clin Sci (Lond). 2000, 98: 507-520. 10.1042/CS19990267.CrossRef
25.
Nevin BJ, Broadley KJ: Nitric oxide in respiratory diseases. Pharmacol Ther. 2002, 95: 259-293. 10.1016/S0163-7258(02)00262-0.CrossRefPubMed
26.
Bredt DS: Endogenous nitric oxide synthesis: biological functions and pathophysiology. Free Radic Res. 1999, 31: 577-596. 10.1080/10715769900301161.CrossRefPubMed
27.
Lima B, Lam GK, Xie L, Diesen DL, Villamizar N, Nienaber J, Messina E, Bowles D, Kontos CD, Hare JM, Stamler JS, Rockman HA: Endogenous S-nitrosothiols protect against myocardial injury. Proc Natl Acad Sci USA. 2009, 106: 6297-6302. 10.1073/pnas.0901043106.CrossRefPubMedPubMedCentral
28.
Naseem KM: The role of nitric oxide in cardiovascular diseases. Mol Aspects Med. 2005, 26: 33-65. 10.1016/j.mam.2004.09.003.CrossRefPubMed
29.
Savidge TC, Newman P, Pothoulakis C, Ruhl A, Neunlist M, Bourreille A, Hurst R, Sofroniew MV: Enteric glia regulate intestinal barrier function and inflammation via release of S-nitrosoglutathione. Gastroenterology. 2007, 132: 1344-1358. 10.1053/j.gastro.2007.01.051.CrossRefPubMed
30.
Savidge TC, Sofroniew MV, Neunlist M: Starring roles for astroglia in barrier pathologies of gut and brain. Lab Invest. 2007, 87: 731-736. 10.1038/labinvest.3700600.CrossRefPubMed
31.
Green LS, Chun LE, Patton AK, Sun X, Rosenthal GJ, Richards JP: Mechanism of inhibition for N6022, a first-in-class drug targeting S-nitrosoglutathione reductase. Biochemistry. 2012, 51: 2157-2168. 10.1021/bi201785u.CrossRefPubMed
32.
Sun X, Wasley J, Qiu J, Blonder J, Stout A, Green L, Strong S, Colagiovanni D, Richards J, Mutka S, Chun L, Rosenthal G: Discovery of S-nitrosoglutathione reductase inhibitors: potential agents for the treatment of asthma and other inflammatory diseases. ACS Med Chem Lett. 2011, 2: 402-406. 10.1021/ml200045s.CrossRefPubMedPubMedCentral
33.
Hamelmann E, Schwarze J, Takeda K, Oshiba A, Larsen GL, Irvin CG, Gelfand EW: Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography. Am J Respir Crit Care Med. 1997, 156: 766-775. 10.1164/ajrccm.156.3.9606031.CrossRefPubMed
34.
Colagiovanni DB, Drolet DW, Langlois-Forget E, Piche MP, Looker D, Rosenthal GJ: A nonclinical safety and pharmacokinetic evaluation of N6022: a first-in-class S-nitrosoglutathione reductase inhibitor for the treatment of asthma. Regul Toxicol Pharmacol. 2012, 62: 115-124. 10.1016/j.yrtph.2011.12.012.CrossRefPubMed
35.
Basu S, Wang X, Gladwin MT, Kim-Shapiro DB: Chemiluminescent detection of S-nitrosated proteins: comparison of tri-iodide, copper/CO/cysteine, and modified copper/cysteine methods. Methods Enzymol. 2008, 440: 137-156.CrossRefPubMed
36.
Feil R, Kemp-Harper B: cGMP signalling: from bench to bedside. Conference on cGMP generators, effectors and therapeutic implications. EMBO Rep. 2006, 7: 149-153. 10.1038/sj.embor.7400627.CrossRefPubMed
37.
Janssen-Heininger YM, Poynter ME, Aesif SW, Pantano C, Ather JL, Reynaert NL, Ckless K, Anathy V, Van DV, Irvin CG, Van DV: Nuclear factor kappaB, airway epithelium, and asthma: avenues for redox control. Proc Am Thorac Soc. 2009, 6: 249-255. 10.1513/pats.200806-054RM.CrossRefPubMedPubMedCentral
38.
Marshall HE, Hess DT, Stamler JS: S-nitrosylation: physiological regulation of NF-kappaB. Proc Natl Acad Sci U S A. 2004, 101: 8841-8842. 10.1073/pnas.0403034101.CrossRefPubMedPubMedCentral
39.
Lundberg JO, Weitzberg E, Gladwin MT: The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov. 2008, 7: 156-167. 10.1038/nrd2466.CrossRefPubMed
40.
Mattos W, Lim S, Russell R, Jatakanon A, Chung KF, Barnes PJ: Matrix metalloproteinase-9 expression in asthma: effect of asthma severity, allergen challenge, and inhaled corticosteroids. Chest. 2002, 122: 1543-1552. 10.1378/chest.122.5.1543.CrossRefPubMed
41.
Ying S, Meng Q, Zeibecoglou K, Robinson DS, Macfarlane A, Humbert M, Kay AB: Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (Intrinsic) asthmatics. J Immunol. 1999, 163: 6321-6329.PubMed
42.
Kleinbongard P, Dejam A, Lauer T, Rassaf T, Schindler A, Picker O, Scheeren T, Godecke A, Schrader J, Schulz R, Heusch G, Schaub GA, Bryan NS, Feelisch M, Kelm M: Plasma nitrite reflects constitutive nitric oxide synthase activity in mammals. Free Radic Biol Med. 2003, 35: 790-796. 10.1016/S0891-5849(03)00406-4.CrossRefPubMed
43.
Metzger IF, Sertorio JT, Tanus-Santos JE: Relationship between systemic nitric oxide metabolites and cyclic GMP in healthy male volunteers. Acta Physiol (Oxf). 2006, 188: 123-127. 10.1111/j.1748-1716.2006.01612.x.CrossRef
44.
Kelleher ZT, Matsumoto A, Stamler JS, Marshall HE: NOS2 regulation of NF-kappaB by S-nitrosylation of p65. J Biol Chem. 2007, 282: 30667-30672. 10.1074/jbc.M705929200.CrossRefPubMed
45.
Sanghani PC, Davis WI, Fears SL, Green SL, Zhai L, Tang Y, Martin E, Bryan NS, Sanghani SP: Kinetic and cellular characterization of novel inhibitors of S-nitrosoglutathione reductase. J Biol Chem. 2009, 284: 24354-24362. 10.1074/jbc.M109.019919.CrossRefPubMedPubMedCentral
46.
Chen Q, Sievers RE, Varga M, Kharait S, Haddad DJ, Patton AK, Delany CS, Mutka SC, Blonder JP, Dube GP, Rosenthal GJ, Springer ML: Pharmacological inhibition of S-nitrosoglutathione reductase improves endothelial vasodilatory function in rats in vivo. J Appl Physiol. 2013, 114: 752-760. 10.1152/japplphysiol.01302.2012.CrossRefPubMedPubMedCentral
47.
Yates DH: Role of exhaled nitric oxide in asthma. Immunol Cell Biol. 2001, 79: 178-190. 10.1046/j.1440-1711.2001.00990.x.CrossRefPubMed
48.
Ricciardolo FL, Di SA, Sabatini F, Folkerts G: Reactive nitrogen species in the respiratory tract. Eur J Pharmacol. 2006, 533: 240-252. 10.1016/j.ejphar.2005.12.057.CrossRefPubMed
49.
Foster MW, Yang Z, Gooden DM, Thompson JW, Ball CH, Turner ME, Hou Y, Pi J, Moseley MA, Que L: Proteonomic characterization by S-nitrosogluthatione reductase inhibition. J Proteome Res. 2012, 11: 2480-2491. 10.1021/pr201180m.CrossRefPubMedPubMedCentral
50.
Foster MW, Yang Z, Potts EN, Foster WM, Que LG: S-nitrosoglutathione supplementation to ovalbumin-sensitized and -challenged mice ameliorates methacholine-induced bronchoconstriction. Am J Physiol Lung Cell Mol Physiol. 2011, 301: L739-L744. 10.1152/ajplung.00134.2011.CrossRefPubMedPubMedCentral
51.
Blonder JP, Mutka SC, Drolet DW, Damaj B, Spicer D, Russell V, Sun X, Rosenthal GJ, Scoggin C: Oral S-nitrosoglutathione reductase inhibitors attenuate pulmonary inflammation and decrease airspace enlargement in experimental models of chornic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011, 183 (1): A6433-A6433.
52.
Blonder JP, Mutka SC, Sun X, Drolet DW, Colagiovanni DB, Lyng G, Scoggin C, Rosenthal GJ: S-nitrosoglutathione reductase inhibitors for the prevention and treatment of experimental DSS colitis. Advances in Inflammatory Bowel Diseases Crohn’s & Colitis Foundations Clinical & Research Conference. 2011, Imedex, LLC: Proceedings, P251-P251.
53.
Cox AG, Saunders DC, Kelsey PB, Conway AA, Tesmenitsky Y, Marchini JF, Brown KK, Stamler JS, Colagiovanni DB, Rosenthal GJ, Croce KJ, North TE, Goessling W: S-nitrosothiol signaling regulates liver development and improves outcome following toxic liver injury. Cell Reports. 2013, 6: 1-14.
54.
Bates J, Irvin C, Brusasco V, Drazen J, Fredberg J, Loring S, Eidelman D, Ludwig M, Macklem P, Martin J, Milic-Emili J, Hantos Z, Hyatt R, Lai-Fook S, Leff A, Solway J, Lutchen K, Suki B, Mitzner W, Pare P, Pride N, Sly P: The use and misuse of Penh in animal models of lung disease. Am J Respir Cell Mol Biol. 2004, 31: 373-374. 10.1165/ajrcmb.31.3.1.CrossRefPubMed
55.
56.
Pinder AG, Rogers SC, Khalatbari A, Ingram TE, James PE: The measurement of nitric oxide and its metabolites in biological samples by ozone-based chemiluminescence. Methods Mol Biol. 2008, 476: 11-28.PubMed
57.
Yang BK, Vivas EX, Reiter CD, Gladwin MT: Methodologies for the sensitive and specific measurement of S-nitrosothiols, iron-nitrosyls, and nitrite in biological samples. Free Radic Res. 2003, 37: 1-10.CrossRefPubMed
58.
Broniowska KA, Diers AR, Hogg N: S-nitrosoglutathione. Biochim Biophys Acta. 1830, 2013: 3173-3181.
59.
Henderson EM, Gaston B: SNOR and wheeze: the asthma enzyme?. Trends Mol Med. 2005, 11: 481-484. 10.1016/j.molmed.2005.09.009.CrossRefPubMed
60.
Dweik RA, Comhair SA, Gaston B, Thunnissen FB, Farver C, Thomassen MJ, Kavuru M, Hammel J, Abu-Soud HM, Erzurum SC: NO chemical events in the human airway during the immediate and late antigen-induced asthmatic response. Proc Natl Acad Sci USA. 2001, 98: 2622-2627. 10.1073/pnas.051629498.CrossRefPubMedPubMedCentral
Metadata
Title
Pharmacologic inhibition of S-nitrosoglutathione reductase protects against experimental asthma in BALB/c mice through attenuation of both bronchoconstriction and inflammation
Authors
Joan P Blonder
Sarah C Mutka
Xicheng Sun
Jian Qiu
Lucia H Green
Navdeep K Mehra
Ramakrishna Boyanapalli
Michael Suniga
Kirsten Look
Chris Delany
Jane P Richards
Doug Looker
Charles Scoggin
Gary J Rosenthal
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2014
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/1471-2466-14-3

Other articles of this Issue 1/2014

BMC Pulmonary Medicine 1/2014 Go to the issue

Research article

Clinical significance of mTOR, ZEB1, ROCK1 expression in lung tissues of pulmonary fibrosis patients

Research article

Treatment adherence and health outcomes in patients with bronchiectasis

Research article

Prognosis of patients with suspected pulmonary embolism in Buenos Aires: a prospective cohort study

Research article

Significance of fractional exhaled nitric oxide in chronic eosinophilic pneumonia: a retrospective cohort study

Research article

A systematic review on tracheostomy decannulation: a proposal of a quantitative semiquantitative clinical score

Study protocol

Epigenetics modifications and Subclinical Atherosclerosis in Obstructive Sleep Apnea: The EPIOSA study
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits